LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Innocoll Holdings plc (“Innocoll” or the “Company”) (Nasdaq: INNL). Investors who purchased or otherwise acquired shares between March 17, 2016 and December 29, 2016 inclusive (the “Class Period”), are encouraged to contact the firm by the March 27, 2017 lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the complaint, the Company made false and/or misleading statements and/or failed to disclose that: Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; that due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and that as a result of the above, Innocoll’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When this news was revealed, shares of Innocoll fell in value, causing investors harm.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.